Blue Trust Inc. Grows Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Blue Trust Inc. raised its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 31.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,579 shares of the biopharmaceutical company’s stock after purchasing an additional 376 shares during the quarter. Blue Trust Inc.’s holdings in Royalty Pharma were worth $45,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. 1834 Investment Advisors Co. acquired a new stake in shares of Royalty Pharma during the 4th quarter valued at approximately $242,000. Fifth Third Bancorp lifted its position in shares of Royalty Pharma by 187.1% during the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 997 shares during the period. Impact Partnership Wealth LLC acquired a new stake in shares of Royalty Pharma during the 4th quarter valued at approximately $467,000. Ballentine Partners LLC acquired a new stake in shares of Royalty Pharma during the 4th quarter valued at approximately $200,000. Finally, Brooklyn Investment Group lifted its position in shares of Royalty Pharma by 1,006.9% during the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 876 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Trading Up 1.1 %

Shares of RPRX opened at $31.73 on Monday. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $32.21. The company has a market capitalization of $18.69 billion, a PE ratio of 16.44 and a beta of 0.49. The stock has a fifty day moving average of $27.83 and a two-hundred day moving average of $27.64. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be issued a dividend of $0.22 per share. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Friday, February 21st. This represents a $0.88 annualized dividend and a dividend yield of 2.77%. Royalty Pharma’s dividend payout ratio (DPR) is 43.52%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Citigroup reduced their price target on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, October 25th. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. Finally, StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Royalty Pharma has a consensus rating of “Buy” and a consensus target price of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.